Exploratory analysis of the phase 3 IMerge trial in transfusion-dependent lower-risk MDS: imetelstat led to greater sustained falls in mutation variant allele frequency than placebo, which was associated with longer red cell transfusion independence.
Secondary analysis
Santini et al. Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat